Terns Pharmaceuticals, Inc.
TERN
$25.79
-$1.74-6.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.51% | -14.22% | -13.43% | -18.69% | -21.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.50% | -2.33% | 0.00% | -0.67% | 4.88% |
| Operating Income | -8.50% | 2.33% | 0.00% | 0.67% | -4.88% |
| Income Before Tax | -7.28% | 4.33% | 0.71% | 1.53% | -3.90% |
| Income Tax Expenses | -11.52% | -4.15% | -9.06% | 8.79% | -47.05% |
| Earnings from Continuing Operations | -7.22% | 4.33% | 0.73% | 1.50% | -3.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.22% | 4.33% | 0.73% | 1.50% | -3.60% |
| EBIT | -8.50% | 2.33% | 0.00% | 0.67% | -4.88% |
| EBITDA | -8.71% | 2.25% | -0.01% | 0.70% | -4.88% |
| EPS Basic | 12.44% | 20.36% | 13.56% | 10.99% | 6.81% |
| Normalized Basic EPS | 12.39% | 20.36% | 13.53% | 11.02% | 6.47% |
| EPS Diluted | 12.44% | 20.36% | 13.56% | 10.99% | 6.81% |
| Normalized Diluted EPS | 12.39% | 20.36% | 13.53% | 11.02% | 6.47% |
| Average Basic Shares Outstanding | 22.40% | 20.29% | 15.66% | 11.55% | 11.83% |
| Average Diluted Shares Outstanding | 22.40% | 20.29% | 15.66% | 11.55% | 11.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |